Navigation Links
Synthetic Biologics Announces Completion of Enrollment in 164 Patient Clinical Trial of Oral Trimesta™ for Multiple Sclerosis
Date:3/14/2012

is available at http://www.clinicaltrials.gov/ct2/show/NCT00451204.

Current sales of injectable disease-modifying therapies for MS are estimated at $8.9 billion annually.  According to various reports, sales of oral disease-modifying therapies for MS, of which Trimesta™ if and when approved would be in such class, are anticipated to exceed $5 billion annually by 2017.

"We are pleased to complete the enrollment of a total of 164 patients in this landmark MS trial," said Rhonda Voskuhl, M.D., Director, University of California, Los Angeles (UCLA) Multiple Sclerosis Program, UCLA Department of Neurology, and lead Principal Investigator of the trial. "In the United States alone, over 200 people per week are diagnosed with MS, and approximately 70% of them are women. Typically, relapsing-remitting MS is distinguished from the other forms of MS by the relapses, or attacks of declining neurologic function, followed by periods of remission. With this trial evaluating oral estriol (Trimesta), we would expect to demonstrate a reduction in the rate of relapses in these MS patients."

About Trimesta (oral estriol)

Trimesta is Synthetic Biologics' proprietary drug candidate for the treatment of relapsing-remitting MS in women. Estriol has been approved and marketed for over 40 years throughout Europe and Asia for the treatment of post-menopausal hot flashes. It has never been approved by the FDA for any indication in the United States.

It has been scientifically documented that pregnant women with certain autoimmune diseases experience a spontaneous reduction of disease symptoms during pregnancy, particularly in the third trimester. The PRIMS (Pregnancy In Multiple Sclerosis) study, a landmark clinical study published in the New England Journal of Medicine followed 254 women with MS during 269 pregnancies, and for up to one year after delivery. The PRIMS s
'/>"/>

SOURCE Synthetic Biologics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Synthetic Biologics to Present at ROTH Annual Growth Stock Conference
2. Adeona Becomes Synthetic Biologics, Inc.
3. Startling results in synthetic chemistry presented in Nature Chemistry
4. New England Biolabs Signs Agreement with Synthetic Genomics Inc. to Launch Gibson Assembly™ Master Mix for Molecular and Synthetic Biology Applications
5. Synthetic Genomics Inc. Hires Industry Leader George E. Stagnitti to Head Food and Nutritional Products Development Program
6. Synthetic Biology: Emerging Global Markets
7. "Sitting Ducks" No Longer: Advance Flu Warning Permits Creation of Replikins Custom Synthetic Flu Vaccine in Animals
8. Synthetic Genomics Inc. and Plenus, S.A. de C.V. Form New Sustainable Agriculture Company, Agradis, Inc. to Develop and Commercialize Products Using Genomic Technologies
9. Swedish University Hospital Improves Monitoring of Treatment Efficacy in Multiple Sclerosis With Synthetic MRI Innovation
10. Kuros Announces Allowance of European Patent for Synthetic Biomaterials
11. Synthetic Genomics Inc. Appoints Joseph Mahler as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... DUBLIN , Oct. 22, 2014 ... addition of the "Global DNA Diagnostics Market ... - Size, Share, Global Trends, Company Profiles, Demand, ... 2013 - 2020" report to their offering. ... diagnostics Market (products, applications, techniques, end users and ...
(Date:10/22/2014)... The North American crystal oscillator market report defines and ... forecast of revenue. This market was valued at $531.4 ... million by 2018, at a CAGR of 3.3% from ... the North American crystal oscillator market report, to get ... provides a glimpse of the segmentation of the market, ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 WriteResult, ... services – has been working with a team of ... New Haven Farms Community Farming Collaborative to provide electronic ... solution. The study, which started in May, aims ... that provides participants weekly exposure to and participation in ...
(Date:10/22/2014)... Physicians Choice Laboratory Services (PCLS) ... which enables healthcare providers to individualize therapeutic treatments ... results, healthcare providers are better able to assess ... minimizing risks for adverse drug reactions and interactions. ... FDA [1] more than 2.2 million adverse drug ...
Breaking Biology Technology:Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Forecast to 2020 2Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Forecast to 2020 3The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 2The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 3The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 4myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 2myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 3PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3
... ... of Bavituximab,s Mechanism of Action in ... - Results Further Support Future Clinical Trials Testing Bavituximab in ... Combination With Radiation Therapy -, TUSTIN, Calif., Sept. 4 Peregrine,Pharmaceuticals, Inc. (Nasdaq: ...
... Sept. 4 Alexion,Pharmaceuticals, Inc. (Nasdaq: ALXN ) ... Alexion Pharmaceuticals, will present at the,Bear Stearns 20th Annual ... on Tuesday, September 11, 2007. An audio webcast ... can,access the webcast at: http://www.alexionpharm.com . An archived ...
... To Maintain Roles as Vice Chairman of The Foundry and Advisor ... ... Labs, MENLO PARK, Calif., Sept. 4 Morgenthaler ... and information technology investments, today announced the,addition of Hank Plain as ...
Cached Biology Technology:Study Published in Clinical Cancer Research Confirms Potential Of Peregrine's Bavituximab Combined With Radiation In Lung Cancer 2Study Published in Clinical Cancer Research Confirms Potential Of Peregrine's Bavituximab Combined With Radiation In Lung Cancer 3Study Published in Clinical Cancer Research Confirms Potential Of Peregrine's Bavituximab Combined With Radiation In Lung Cancer 4Study Published in Clinical Cancer Research Confirms Potential Of Peregrine's Bavituximab Combined With Radiation In Lung Cancer 5Hank Plain Joins Morgenthaler Ventures as Partner 2Hank Plain Joins Morgenthaler Ventures as Partner 3
(Date:10/16/2014)... tract infections and worldwide claims the lives of ... Ghent University have succeeded in developing a promising ... , Xavier Saelens (VIB/UGent): "We discovered a ... the development of a novel approach to vaccination ... numerous small children and elderly people." , ...
(Date:10/15/2014)... ,Models of Life, is a non-traditional biophysics textbook and ... book is a journey of discovery into biological systems ... and biological regulation. It is about how our genes ... between the billions of cells in an organism. It ... between principles, which can be found on both large ...
(Date:10/15/2014)... will be awarded the 44th Rosenstiel Award for Distinguished ... pioneering research exploring the mechanisms of genomic instability and ... Alt is the second alumnus to win the Rosenstiel ... in 2003. , Alt is the Charles A. Janeway ... Medical School and an investigator at the Howard Hughes ...
Breaking Biology News(10 mins):New perspectives for development of an RSV vaccine 2New book about life as seen from physics 2Brandeis awards 44th Rosenstiel Award to pioneering geneticist Fred Alt 2
... a medical doctor. Yet he is seen as a hero ... D.H. was diagnosed with terminal lung cancer. , "In 2000 ... few months to live," said Pardini, a professor of biochemistry ... the University of Nevada, Reno. "But five years later, ...
... for treating Parkinson's diseases and other neurodegenerative disorders is getting ... brain is a complex organ with many different types of ... barrier erected by blood vessels and glial cells -- the ... of most drugs from the bloodstream. , But now scientists ...
... of history students have discovered the antler of an Irish Elk ... , Although the exact age of the antler has yet to ... (Megaloceros giganteus) lived around 11,000 years ago. The giant deer roamed ... the end of the last Ice Age, as the glaciers retreated ...
Cached Biology News:The nude mouse tale: Omega-3 fats save the life of a terminal cancer patient 2Engineered Stem Cells Show Promise For Sneaking Drugs Into The Brain 2Engineered Stem Cells Show Promise For Sneaking Drugs Into The Brain 3Students discover 11,000 year old remains of Irish Elk 2
rat Leptin...
...
... with the xPONENT Software Interface is ... assays using Upstate's Beadlyte® reagents. This ... friendly xPONENT software developed by Luminex. ... for commercial or home-made multiplex kits. ...
... L samples, featuring 24-position turntable. Provides up to 30 minutes of walkaway time. Automatic ... and record keeping. RS-232 port. ... ... ...
Biology Products: